Agios Pharmaceuticals | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Agios Pharmaceuticals USD 1.56B 107.68M 2025-03
Alnylam Pharmaceuticals USD 4.21B 26.17M 2025-03
Amgen USD 89.37B 2.47B 2025-03
Arrowhead Research USD 1.01B 126.11M 2024-12
Astellas Pharma JPY 3.34T 112.09B 2025-03
AstraZeneca USD 106.25B 2.22B 2025-03
Bayer EUR 110.85B 3.9B 2024-12
Biogen USD 28.03B 16.2M 2025-03
BioMarin Pharmaceutical USD 7.15B 158.07M 2025-03
Bristol-Myers Squibb USD 92.43B 176M 2025-03
Daiichi Sankyo JPY 3.46T 12.51B 2025-03
Eli Lilly USD 89.39B 10.67B 2025-03
Exelixis USD 2.95B 12.59M 2025-01
Gilead Sciences USD 56.43B 2.56B 2025-03
GlaxoSmithKline GBP 60.71B 1.24B 2025-03
Incyte USD 5.75B 305.04M 2025-03
Ionis Pharmaceuticals USD 2.81B 190.73M 2025-03
Merck USD 115.12B 1.98B 2025-03
Moderna USD 12.7B 1.44B 2025-03
Novartis USD 102.25B 1.28B 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 208.03B 5.37B 2025-03
Regeneron Pharmaceuticals USD 37.55B 214.2M 2025-03
Roche Holding CHF 101.8B 6.02B 2024-12
Sarepta Therapeutics USD 3.47B 497.79M 2025-03
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Agios Pharmaceuticals Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.